House File 2551 H-8151 Amend House File 2551 as follows: 1 1. Page 3, after line 3 by inserting: 2 < g. The aggregate manufacturer-level direct and 3 administrative costs related to marketing and advertising of 4 the prescription drug for the immediately preceding calendar 5 year. > 6 2. Page 7, after line 3 by inserting: 7 < ___. “Interchangeable biological product” means the same as 8 defined in section 155A.3. > 9 3. Page 7, after line 10 by inserting: 10 < ___. “Specialty drug” means the same as defined in section 11 510E.1. > 12 4. Page 7, line 13, after < or > by inserting < need-based 13 payments paid > 14 5. Page 7, line 17, after < for > by inserting < a specialty 15 drug or > 16 6. Page 7, line 19, after < equivalent > by inserting < or an 17 interchangeable biological product > 18 7. Title page, by striking lines 1 through 3 and inserting 19 < An Act relating to price transparency and cost-sharing for 20 prescription drugs, and including applicability provisions. > 21 8. By renumbering, redesignating, and correcting internal 22 references as necessary. 23 ______________________________ LUNDGREN of Dubuque -1- HF2551.3748 (2) 88 ko/rn 1/ 1 #1. #2. #3. #4. #5. #6. #7. #8.